India’s Genes2Me prepares US expansion with regulatory submissions for sepsis and antimicrobial resistance assays on its OnePCR system, which supports a broad menu of molecular tests including direct-from-blood detection. The firm’s global footprint is growing rapidly with over 150 installed systems and focus on building commercial infrastructure in key regions. The OnePCR platform’s multiplexing capacity and integrated sample-to-answer design positions it favorably to address burgeoning demand for cost-effective real-time PCR diagnostics worldwide.